Suscribirse

“Artificial intelligence”: Which services, which applications, which results and which development today in clinical research? Which impact on the quality of care? Which recommendations? - 23/02/19

Doi : 10.1016/j.therap.2018.12.003 
Vincent Diebolt a, , Isaac Azancot b, François-Henri Boissel c

The participants of Giens XXXIV round table 'Hot topic N° 2'

Isabelle Adenot d, Christine Balague e, Philippe Barthélémy f, Nacer Boubenna g, Hélène Coulonjou h, Xosé Fernandez i, Enguerrand Habran j, Françoise Lethiec k, Juliette Longin l, Anne Metzinger m, Yvon Merlière n, Emmanuel Pham o, Pierre Philip p, Thomas Roche q, William Saurin r, Anny Tirel s, Emmanuelle Voisin t, Thierry Marchal u
d Haute autorité de santé, 93218 Saint-Denis la Plaine, France 
e Institut mines-telecom business school, 91011 Evry, France 
f Astrazeneca, 92400 Courbevoie, France 
g Inserm transfert, 75013 Paris, France 
h DRCI, AP–HP, 75475 Paris, France 
i Institut Curie, 75005 Paris, France 
j Fonds FHF recherche et innovation, 75993 Paris, France 
k Janssen Cilag, 92787 Issy-lès-Moulineaux, France 
l Merck santé, 69008 Lyon, France 
m Hospices civils de Lyon, HCL, DRCI, 69229 Lyon, France 
n CNAMTS, 75986 Paris, France 
o IPSEN, 91940 Les Ulis, France 
p Université de Bordeaux, CHU de Bordeaux, 33076 Bordeaux, France 
q Delsol avocats, 69001 Lyon, France 
r Dassault systèmes–3DS, 78946 Vélizy-Villacoublay, France 
s MSD, 92400 Courbevoie, France 
t Voisin consulting life science, 92100 Boulogne, France 
u ANSYS, université catholique de Louvain, 1348 Louvain la Neuve, Belgium 

a F-CRIN, pavillon Leriche, hôpital Purpan, place du Dr-Blayac, 31059 Toulouse cedex 9, France 
b Hôpital Lariboisière, AP–HP, 75475 Paris, France 
c Novadiscovery, 69009 Lyon, France 

Corresponding author.

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.

Conéctese para beneficiarse!

Summary

Artificial intelligence (AI), beyond the concrete applications that have already become part of our daily lives, makes it possible to process numerous and heterogeneous data and knowledge, and to understand potentially complex and abstract rules in a manner human intelligence can but without human intervention. AI combines two properties, self-learning by the successive and repetitive processing of data as well as the capacity to adapt, that is to say the possibility for a scripted program to deal with multiple situations likely to vary over time. Roundtable experts confirmed the potential contribution and theoretical benefit of AI in clinical research and in improving the efficiency of patient care. Experts also measured, as is the case for any new process that people need to get accustomed to, its impact on practices and mindset. To maximize the benefits of AI, four critical points have been identified. The careful consideration of these four points conditions the technical integration and the appropriation by all actors of the life science spectrum: researchers, regulators, drug developers, care establishments, medical practitioners and, above all, patients and the civil society. 1st critical point: produce tangible demonstrations of the contributions of AI in clinical research by quantifying its benefits. 2nd critical point: build trust to foster dissemination and acceptability of AI in healthcare thanks to an adapted regulatory framework. 3rd critical point: ensure the availability of technical skills, which implies an investment in training, the attractiveness of the health sector relative to tech-heavy sectors and the development of ergonomic data collection tools for all health operators. 4th critical point: organize a system of governance for a distributed and secure model at the national level to aggregate the information and services existing at the local level. Thirty-seven concrete recommendations have been formulated which should pave the way for a widespread adoption of AI in clinical research. In this context, the French “Health data hub” initiative constitutes an ideal opportunity.

El texto completo de este artículo está disponible en PDF.

Keywords : AI, Data, Knowledge, Clinical research, Clinical trials, Real-life studies, Assessment, Training, Interdisciplinary, Interoperability, Governance


Esquema


 Articles, analyses and proposals from Giens workshops are those of the authors and do not prejudice the proposition of their parent organization.


© 2018  Publicado por Elsevier Masson SAS.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 74 - N° 1

P. 155-164 - février 2019 Regresar al número
Artículo precedente Artículo precedente
  • « Intelligence artificielle » : quels services, quelles applications, quels résultats et quelle valorisation aujourd’hui en recherche clinique ? Quel impact sur la qualité des soins ? Quelles recommandations ?
  • Vincent Diebolt, Isaac Azancot, François-Henri Boissel
| Artículo siguiente Artículo siguiente
  • Le professeur André Escousse nous a quittés le 24 octobre 2018
  • Catherine Sgro

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2024 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.